Form 4: TriSalus Life Sciences Director Liselotte Hyveled Acquires Stock Options
SEC Form 4
Director Liselotte Hyveled of TriSalus Life Sciences, Inc. reports the acquisition of stock options on May 6, 2024.
Summary
- Liselotte Hyveled, a director of TriSalus Life Sciences, Inc., filed a Form 4 on May 7, 2024, reporting a transaction.
- On May 6, 2024, Hyveled acquired stock options for 35,000 shares of common stock at an exercise price of $9.62.
- These options vest in three equal annual installments starting from May 6, 2024, contingent upon continued service with the issuer.
- Following the transaction, Hyveled directly owns options for 35,000 shares.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard stock option grant to a director. It suggests confidence but doesn't provide concrete financial data.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting of the stock options is contingent upon the director's continued service with the company.
Industry Context
Stock option grants are a common form of executive compensation in the life sciences industry, aligning the interests of management with those of shareholders.
Stakeholder Impact
- The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 05/06/2024 | Date of the stock option transaction. |
| 05/06/2024 | Vesting commencement date for the stock options. |
| 05/05/2034 | Expiration date of the stock options. |
| 05/07/2024 | Date the Form 4 was filed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.